Definium Therapeutics (DFTX) Accumulated Expenses (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Accumulated Expenses data on file, last reported at $7.4 million in Q1 2026.

• Quarterly Accumulated Expenses rose 69.98% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 million (up 69.98% YoY) and the FY2025 annual result came in at $20.4 million, up 59.37% from the prior year.
• Accumulated Expenses eased to $7.4 million in Q1 2026 per DFTX's latest filing, from $20.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $20.4 million in Q4 2025 and bottomed at $1.6 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $5.9 million (2022), against an average of $7.7 million.
• The widest annual swing landed in 2023, when Accumulated Expenses sank 74.93%; it then surged 395.65% in 2025.
• Tracing DFTX's Accumulated Expenses over 5 years: stood at $5.9 million in 2022, then soared by 97.96% to $11.6 million in 2023, then increased by 10.27% to $12.8 million in 2024, then soared by 59.37% to $20.4 million in 2025, then tumbled by 63.74% to $7.4 million in 2026.
• Per Business Quant, the three latest DFTX Accumulated Expenses figures stand at $7.4 million (Q1 2026), $20.4 million (Q4 2025), and $19.0 million (Q3 2025).

Peer Comparison